News & Media

Read about our latest news and initiatives, and find more information about Acadia.

Featured Perspectives

July 21, 2023 Employee Spotlight

Meet the Trailblazers: Holly Valdiviez

June 2, 2023 Perspective

Before, During and After Pride Month, All are Welcome

May 19, 2023 Perspective

Raising Awareness about Mental Health, Reducing the Stigma of Schizophrenia

View All

Latest News Releases

September 22, 2023 General News

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 19, 2023 General News

Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications

September 18, 2023 Company Statement

Acadia Pharmaceuticals Announces Label Update for NUPLAZID® (pimavanserin)

View All

About Acadia

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years, we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders.

Learn More